| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Toripalimab Basic information |
| Product Name: | Toripalimab | | Synonyms: | Toripalimab;Research Grade Toripalimab(DHH02208);Research Grade Toripalimab;Toripalimab (anti-PD-1);Immunoglobulin G4, anti-(human programmed cell death protein 1) (human monoclonal JS001 γ4-chain), disulfide with human monoclonal JS001 κ-chain, dimer (ACI) | | CAS: | 1924598-82-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Toripalimab Structure]() |
| | Toripalimab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Toripalimab Usage And Synthesis |
| Uses | Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma[1]. | | in vivo | Toripalimab (0.3-10 mg/kg; i.p.; twice a week, total 6 times) exhibits substantial tumor suppressive efficacy in a dose-dependent manner[3].
| Animal Model: | A genetically modified mouse strain with human PD-1 knocked in (were subcutaneously inoculated with 1 × 106 MC38 cells)[3] | | Dosage: | 0.3, 1, 3, 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); twice a week, total 6 times | | Result: | Inhibition of tumor growth was observed in a dose-dependent manner with substantial antitumor efficacy in 1, 3, and 10 mg/kg treatment groups.
Decreased significantly at the end of the observation period (day 23)
|
| | References | [1] Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. DOI:10.3389/fimmu.2021.730666
[2] Keam SJ. Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578. DOI:10.1007/s40265-019-01076-2
[3] Liu H, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690. DOI:10.1080/19420862.2019.1596513 |
| | Toripalimab Preparation Products And Raw materials |
|